PubMed Health⌕ Search

Biomedical subjects

Suresh Senan

Publications and source records attributed to Suresh Senan.

30 records · Page 2Linked to original sources
PubMed2003

Tumor location cannot predict the mobility of lung tumors: a 3D analysis of data generated from multiple CT scans.

PURPOSE: There is limited information available on the three-dimensional (3D) motion of lung tumors. Data derived from multiple planning computed tomographic (CT) scans were used to characterize the 3D movement of small peripheral lung tumors. METHODS AND MATERIALS: A total of 29 data sets from patients with Stage I non-small-cell lung cancer (NSCLC), each of which consisted of three "rapid" and three "slow" planning CT scans, were analyzed. All six scans were coregistered, and contoured gross tumor volumes (GTVs) were expanded by 5 mm to derive clinical target volumes (CTVs). Two-dimensional and 3D displacement vectors of the individual CTVs, relative to an "optimal" CTV derived from all six scans, were generated. Tumor mobility was correlated with location. Three-dimensional margins, which had to be added to individual CTVs to ensure coverage of "optimal" CTVs, were determined. RESULTS: No significant correlation was observed between the anatomic location of tumors and the extent of mobility in the x, y, and z axes. However, supradiaphragmatic lesions exhibited more mobility, particularly in the craniocaudal direction. The addition of a 3D margin of 5 mm to a single slow CTV ensured full coverage of the "optimal CTV". CONCLUSIONS: Lung tumors demonstrate significant mobility in all directions, and this did not closely correlate with anatomic location. Individualized assessment of tumor mobility remains necessary, and is possible when the CTV derived from a single slow scan is used for radiotherapy planning.

Carcinoma, Non-Small-Cell Lung↗
PubMed2003

Are multiple CT scans required for planning curative radiotherapy in lung tumors of the lower lobe?

PURPOSE: Lung tumors located in the lower lobe are the most mobile. Multiple computed tomographic (CT) scans, which had been performed for radiotherapy planning, were analyzed to determine the minimal number of required scans. METHODS AND MATERIALS: Six spiral CT scans (3 rapid and 3 slow) from 7 such patients were coregistered. Reproducibility of target volumes was defined as the ratio between the overlapping and encompassing volume (COM/SUM) from scans derived using one technique. Volumetric and dosimetric analyses were performed. RESULTS: Slow CT scans generated larger and more reproducible target volumes than rapid planning scans, with a mean COM/SUM ratio of 71.9 +/- 8.7% and 58.0 +/- 12.7%, respectively. When only a single slow CT scan was used for planning, the addition of a symmetrical 3D margin of 5 mm ensured 99% coverage of the "optimal" target volume, which was derived from summation of target volumes from all six scans. CONCLUSION: Planning target volumes (PTVs) derived from a single slow CT scan plus a 5-mm margin covered the "optimal" PTVs generated from six scans. Although these "slow PTVs" were larger, the increase in V(20) (the volume of lung tissue receiving a dose > or = 20 Gy) was limited. This indicates that only two CT scans, i.e., a full rapid scan of the entire thorax and a limited slow scan, are necessary for treatment planning in peripheral lung cancers.

Artifacts↗
PubMed2003

Procedures for high precision setup verification and correction of lung cancer patients using CT-simulation and digitally reconstructed radiographs (DRR).

PURPOSE: In a recent study, large systematic setup errors were detected in patients with lung cancer when a conventional simulation procedure was used to define and mark the treatment isocenter. In the present study, we describe a procedure to omit the session at a conventional simulator to remove simulation errors entirely. Isocenter definition and verification was performed at a computed tomography (CT) simulator, and digitally reconstructed radiographs (DRRs) were used for setup verification and correction at the treatment unit. METHODS AND MATERIALS: A CT simulation protocol was developed, in which radiopaque markers were used to verify the coincidence of the isocenter marked on the patients' skin with the isocenter defined in the planning CT scan. This protocol was evaluated for 20 patients. Subsequently, electronic portal images were acquired at the treatment unit. The three-dimensional setup error was established from a template match of the appropriate anatomy visible in two orthogonal beams with the corresponding anatomy in DRRs. An offline setup correction protocol was applied to reduce systematic setup errors. RESULTS: For all patients, the skin marks defined the planning CT scan isocenter to within +/- 1.5 mm in each of the three main directions. Random setup errors at the treatment unit were 1.8, 2.0, and 1.9 mm (1 SD) for the lateral (x), the superior-inferior (y), and the anterior-posterior (z) directions, respectively. With the use of the correction protocol, the systematic errors for x, y, and z were 1.5, 1.5, and 1.3 mm (1 SD). CONCLUSIONS: Because the distributions of treatment setup errors measured against DRRs obtained in our CT simulation were equal to previously obtained distributions measured against simulator films, conventional simulation can be omitted and DRRs are well-suited for setup verification. By adopting our CT simulation procedure, the large systematic simulation setup errors, which remain hidden if a conventional simulation is performed, can be avoided.

Carcinoma, Non-Small-Cell Lung↗
PubMed2003

Indications and limitations of radiotherapy in malignant pleural mesothelioma.

In patients with malignant pleural mesothelioma, radiotherapy is useful in the palliation of symptoms of chest pain and painful masses. Prophylactic chest wall irradiation appears to reduce the incidence of chest wall recurrences at incision sites. An area of active ongoing research is the role of high-dose hemithorax irradiation after extrapleural pneumonectomy for early stage disease. In carefully staged patients, this approach has resulted in a marked reduction in local tumor recurrences, although nearly one half of patients subsequently developed isolated distant metastases. Relevant issues for planning postoperative radiotherapy in such patients are highlighted. These multimodality protocols await evaluation within prospective randomized clinical trials, and effective systemic chemotherapy regimens will also need to be integrated into such approaches.

Chest Pain↗
PubMed2002

Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy.

PURPOSE: To establish the recurrence patterns when elective mediastinal irradiation was omitted, patients with Stage III non-small-cell lung cancer were treated with sequential chemotherapy (CHT) and involved-field radiotherapy (RT). METHODS AND MATERIALS: Fifty patients were treated with either two or four cycles of induction CHT, followed by once-daily involved-field RT to 70 Gy, delivered using three-dimensional treatment planning. The contoured gross tumor volume consisted of the pre-CHT tumor volume and nodes with a short-axis diameter of > or = 1 cm. Patients were reevaluated at 3 and 6 months after RT using bronchoscopy and chest CT. Elective nodal failure was defined as recurrence in the regional nodes outside the clinical target volume, in the absence of in-field failure. RESULTS: Of 43 patients who received doses > or = 50 Gy, 35% were disease free at last follow-up; in-field recurrences developed in 27% (of whom 16% had exclusively in-field recurrences); 18% had distant metastases exclusively. No elective nodal failure was observed. The median actuarial overall survival was 18 months (95% confidence interval 14-22) and the median progression-free survival was 12 months (95% confidence interval 6-18). CONCLUSION: Omitting elective mediastinal irradiation did not result in isolated nodal failure. Future studies of concurrent CHT and RT for Stage III non-small-cell lung cancer should use involved-field RT to limit toxicity.

Adult↗
PubMed2002

What margins are necessary for incorporating mediastinal nodal mobility into involved-field radiotherapy for lung cancer?

PURPOSE: The mobility of mediastinal nodes was studied on multiple CT scans of the thorax from patients with non-small-cell lung cancer. PATIENTS AND METHODS: A total of 10 enlarged mediastinal nodes/masses were identified in 8 patients with non-small-cell lung cancer. Nodal locations were classified using the Naruke/ATS-LCSG system, and between 3 and 6 scans were available for each site. The CT data sets were coregistered, and the contoured nodes were automatically projected onto the initial planning CT scan. An encompassing nodal volume (ENV) of all contours of a particular node was manually contoured on all scans. Individual nodal volumes were expanded in three dimensions to establish additional margins required to encompass the ENV. RESULTS: The mean volume of nodes studied ranged from 0.8 to 23.2 cc. The addition to individual nodes of a margin of 5 mm was found to result in a mean ENV coverage of >or=95% at all sites. For individual nodes at locations N4R, N5, and N6, however, the coverage ranged from 87.8% to 92.6%. CONCLUSION: The addition of a margin of 5 mm to individual mediastinal nodes seems to be adequate to account for variations in both contouring and mobility.

Humans↗
PubMed2002

Curative radiotherapy for a second primary lung cancer arising after pneumonectomy -- techniques and results.

BACKGROUND AND PURPOSE: Only limited data exist on the outcome of curative radiotherapy in patients who develop a second primary lung tumour after pneumonectomy. The treatment of eight such patients is described. MATERIALS AND METHODS: The case records of patients who underwent curative radiotherapy for stage I non-small cell lung cancer after a previous pneumonectomy were reviewed. Treatment was delivered using 3D external radiotherapy to a dose of 50-70 Gy, in once-daily fractions of 2-2.5 Gy. An endobronchial brachytherapy boost was used in three patients. Original treatments were re-planned in an attempt to minimize the volume of irradiated lung. RESULTS: A complete remission was achieved in five (of six) evaluable patients, but two patients subsequently developed a local relapse. All patients survived for a minimum of 1 year after treatment. Only one patient developed significant (grade 2) radiation pneumonitis. When treatments were re-planned to optimize beam arrangements, and when customized blocks were used, the mean lung volume receiving > or = 20 Gy (calculated for 70 Gy) decreased from 24.6+/-4.1 (range, 18-31%) to 17.3+/-5.1% (range, 12-26%). Similarly, the radiation conformity index improved from 0.44+/-0.11 to 0.61+/-0.06. CONCLUSIONS: Involved-field radiotherapy can be curative in patients who develop a new lung tumour after pneumonectomy. Recent advances in defining target volumes, treatment planning and delivery are likely to improve upon these results.

Aged↗
PubMed2002

Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer?

AIMS AND BACKGROUND: The high local failure rates observed after radiotherapy in stage I non-small cell lung cancer (NSCLC) may be improved by the use of 3-dimensional conformal radiotherapy (3D CRT). MATERIALS AND METHODS: The case-records of 113 patients who were treated with curative 3D CRT between 1991 and 1999 were analysed. No elective nodal irradiation was performed, and doses of 60Gy or more, in once-daily fractions of between 2 and 3Gy, were prescribed. RESULTS: The median actuarial survival of patients was 20 months, with 1-, 3- and 5-year survival of 71, 25 and 12%, respectively. Local disease progression was the cause of death in 30% of patients, and 22% patients died from distant metastases. Grade 2-3 acute radiation pneumonitis (SWOG) was observed in 6.2% of patients. The median actuarial local progression-free survival (LPFS) was 27 months, with 85 and 43% of patients free from local progression at 1 and 3 years, respectively. Endobronchial tumour extension significantly influenced LPFS, both on univariate (P=0.023) and multivariate analysis (P=0.023). The median actuarial cause-specific survival (CSS) was 19 months, and the respective 1- and 3-year rates were 72 and 30%. Multivariate analysis showed T2 classification (P=0.017) and the presence of endobronchial tumour extension (P=0.029) to be adverse prognostic factors for CSS. On multivariate analysis, T-stage significantly correlated with distant failure (P=0.005). CONCLUSIONS: Local failure rates remain substantial despite the use of 3D CRT for stage I NSCLC. Additional improvements in local control can come about with the use of radiation dose escalation and approaches to address the problem of tumour mobility.

Aged↗
PubMed2002

Can errors in reconstructing pre-chemotherapy target volumes contribute to the inferiority of sequential chemoradiation in stage III non-small cell lung cancer (NSCLC)?

Concurrent chemo-radiotherapy (CT-RT) has been shown to be superior to sequential CT-RT for stage III non-small cell lung cancer (NSCLC). Pre-chemotherapy gross tumor volumes (GTV) are commonly contoured for sequential CT-RT and, as significant inter-clinician variability exists in defining GTV's for lung cancer, we postulated that the poorer local control observed with sequential CT-RT may partly be due to the larger errors in defining GTV after chemotherapy-induced tumor regression. Pre-and post-chemotherapy CT scans for RT planning (RTP) were performed in ten patients who received induction chemotherapy for NSCLC. Image registration of pre- and post-chemotherapy RTP scans was performed for all patients. GTV's were first contoured in the conventional manner by two clinicians, i.e. by visual reconstruction from hard copies of the pre-chemotherapy diagnostic CT scans ('GTV-visual'). A 'GTV-match' was then contoured after image-registration, and the 'gold standard' volume was considered to be the overlap of the 'GTV-match' generated by both clinicians. The 'GTV-match' was on average 31-40% larger than 'GTV-visual'. The mean percentage of the 'gold standard', which was not covered by the 'GTV-visual' was similar for both clinicians, i.e. 26.3+/-12.5 and 28.0+/-15.0%. The inter-clinician agreement in contouring improved after image registration. These data suggest that conventional visual contouring of pre-chemotherapy GTV's may fail to treat the actual pre-chemotherapy tumor volume, and thus confound studies evaluating optimal sequencing of chemo-radiotherapy in NSCLC.

Carcinoma, Non-Small-Cell Lung↗